Provided herein is technology relating to microfluidic devices and particularly, but not exclusively, to devices, methods, systems, and kits for imparting stresses on a fluid flowing through a microfluidic device that is designed to mimic a stress profile of a macrofluidic device or pathology.

The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient. The method preferably includes a step that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.

A method is provided for determining pulmonary embolism and/or increased risk thereof in a human being, comprising collecting a sample of exhalation air from said human being and determining the presence or absence in said exhaled air of one or more biomarkers associated with pulmonary embolism. Additionally, a kit that comprises the means for detecting at least one biomarker associated with pulmonary embolism or risk thereof is provided.

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of ENPP4.

A diagnostic device which enables measurement of fibrinogen concentration in a blood sample. The device comprises; a wettable testing substrate including viewing indicators which allow determination of a status of a test. The substrate has a first end and second end and intermediate therebetween a flow receiving zone, a flow path zone and a reaction zone; the reaction zone pre charged with at least one reagent. A blood sample to be tested is deposited near or in either of said flow receiving zone or said reaction zone, the sample reacting with the reagents inducing clotting of the sample. Water added to a dye added to said reaction zone, advances a distance along said substrate. The distance travelled along the substrate by the dye and through the sample is indicative of a measure of concentration of fibrinogen in said blood sample under test.

The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses FcγRIIa protein-coated particles.

An example method includes: analyzing a clot curve for a test sample that is based on an assay performed on the test sample in order to obtain two or more parameters associated with the clot curve; analyzing the two or more parameters to determine at least one of (i) whether a fibrinogen concentration in the test sample is below a threshold, or (ii) whether there is a therapeutic or pharmaceutical anticoagulant present in the test sample; and outputting, to a user interface, information based on the determination.

Compositions and methods are provided for determining platelet reactivity where the levels of FcγRIIa on the surface of platelets is measured and if the levels of FcγRIIa are greater than a reference value, the platelets have enhanced reactivity.

Compositions and methods are provided for determining platelet reactivity where the levels of FcγRIIa on the surface of platelets is measured and if the levels of FcγRIIa are greater than a reference value, the platelets have enhanced reactivity.